Achieve - ACetazolamide in patients with Heart failure, to decrease weight and relIEVE symptoms

Conditions

Heart failure

Brief summary

Percentage of patients with weight loss > 2kg on connected scale (Remote telemonitoring system) on D5 in each of the two groups (experimental vs control)

Detailed description

Percentage of weight variation between D0 and D5, Diuretic effectiveness on D5 calculated by calculating natriuresis corrected by mg of furosemide equivalence from the urinary ionogram performed on D5, Evolution of NtproBNP between D0 and D5, Evolution of the EQ-5D-5L value between D0 and D5, Evolution of the VAS score for dyspnea between D0 and D5, Rate of unplanned/emergency consultation or hospitalization for HF at D90, Rate of deaths from all causes or for HF at D90, Evolution of clinical (weight, VAS dyspnea, BP, HR, RHF and LHF signs) and biological (NtproBNP) between D5 and D15, Evolution of clinical (weight, VAS dyspnea, BP, HR, RHF and LHF signs) and biological (NtproBNP) at D15

Related papers

No related papers found yet.

Interventions

DRUGDIAMOX* 250mg Tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Percentage of patients with weight loss > 2kg on connected scale (Remote telemonitoring system) on D5 in each of the two groups (experimental vs control)	—

Secondary

Measure	Time frame
Percentage of weight variation between D0 and D5, Diuretic effectiveness on D5 calculated by calculating natriuresis corrected by mg of furosemide equivalence from the urinary ionogram performed on D5, Evolution of NtproBNP between D0 and D5, Evolution of the EQ-5D-5L value between D0 and D5, Evolution of the VAS score for dyspnea between D0 and D5, Rate of unplanned/emergency consultation or hospitalization for HF at D90, Rate of deaths from all causes or for HF at D90, Evolution of clinical (weight, VAS dyspnea, BP, HR, RHF and LHF signs) and biological (NtproBNP) between D5 and D15, Evolution of clinical (weight, VAS dyspnea, BP, HR, RHF and LHF signs) and biological (NtproBNP) at D15	—

Measure

Time frame

Percentage of weight variation between D0 and D5, Diuretic effectiveness on D5 calculated by calculating natriuresis corrected by mg of furosemide equivalence from the urinary ionogram performed on D5, Evolution of NtproBNP between D0 and D5, Evolution of the EQ-5D-5L value between D0 and D5, Evolution of the VAS score for dyspnea between D0 and D5, Rate of unplanned/emergency consultation or hospitalization for HF at D90, Rate of deaths from all causes or for HF at D90, Evolution of clinical (weight, VAS dyspnea, BP, HR, RHF and LHF signs) and biological (NtproBNP) between D5 and D15, Evolution of clinical (weight, VAS dyspnea, BP, HR, RHF and LHF signs) and biological (NtproBNP) at D15

—

Outcome results

None listed